Latest News

World Cancer Day 2017

A truly global event taking place every year on 4 February, World Cancer Day unites the world’s population in the fight against cancer. It aims to save millions of preventable deaths each year by raising awareness and education about the disease, pressing governments and individuals across the world to take action.  Currently, 8.2 million people […]

Read More

Precision medicine demonstrates benefit in late-stage cancer trial

A clinical trial carried out in a diverse set of advanced cancers is the first to demonstrate that use of precision medicine can slow down tumor regrowth.   The trial was carried out at the Gustave Roussy Cancer Campus (Paris, France) and these results were presented recently at the Molecular Analysis for Personalised Therapy Conference […]

Read More

Oncologica UK contributes to setting new guidelines for implementation of Next Generation Sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours. An expert opinion on behalf of IQN Path ASBL.

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL The clinical demand for mutation detection within multiple genes from a single tumour sample requires molecular diagnostic laboratories to develop rapid, high-throughput, highly sensitive, accurate and parallel testing within tight budget […]

Read More

p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.

This new discovery in relation to the molecular circuitry regulation the G1 cell cycle checkpoint provides a unique insight into why the new anti-cancer approach proposed using Cdc7 targeted anti-cancer therapies can act as powerful tumour killing agents but do not affect the normal cells of the body thereby circumventing the toxicity associated with conventional […]

Read More

Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment

Using immunohistochemistry and flow cytometry to define phases of the cell cycle, this study shows that a high proportion of acute myeloid leukaemia (AML) blasts obtained from trephine biopsies are cycling, whereas >95% of peripheral blood-derived blasts are arrested in G1 . Results obtained from bone marrow aspirates are more similar to those from blood […]

Read More

Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint

PURPOSE Cdc7 is a serine/threonine kinase which is responsible for the ‘firing’ of replication origins leading to initiation of DNA replication. Inhibition or depletion of Cdc7 in normal cells triggers a DNA origin activation checkpoint causing a reversible G1 arrest. Here we investigate Cdc7 as a novel therapeutic target in pancreatic cancer. EXPERIMENTAL DESIGN Cdc7 […]

Read More

Precision Medicine is hot topic at ASCO

CHICAGO: A precision medicine approach using a patient’s individual tumor biomarkers to determine the best treatment leads to significantly better outcomes, according to data being presented at this year’s American Society of Clinical Oncology (ASCO) meeting.   A meta-analysis of 346 Phase I clinical trials involving more than 13,000 patients found that patients whose treatment […]

Read More

Cancer treatment untested in many patients with immune problems

Thousands of cancer patients could be spared chemotherapy every year following significant advances in personalised medicine, experts have said. Because of this, patients may find themselves stopping the pills before the first five years, resulting in risks not being lowered.   Instead, targeted drugs created to bring the cancer under control can be selected – […]

Read More

Defining cancers based on genetic ‘fingerprint’ could help personalise treatment

“We’re starting to move from general treatments chosen on the basis of the tissue where the cancer starts and what the cancer looks like, to an era of molecular-designed therapy, targeting a tumour’s genetic fingerprint” – Professor Peter Johnson, Cancer Research UK Doctors are closer to personalising treatment for some cancers as genetic analysis of […]

Read More

Precision medicine can widen cancer care options, studies find

Using a patient’s individual tumor biomarkers to determine the best treatment can improve success rates, studies showed Saturday. Unlike chemotherapy and radiation therapy, targeted medicine allows for the preservation of healthy cells.   This approach, especially immunotherapy, which boosts the immune system to destroy tumor cells — is revolutionizing oncology, according to the study released at […]

Read More

Targeted cancer care to spare thousands of patients chemotherapy

Precision medicine is about finding the right key for the lock, finding out what it is that is driving the tumour, what makes it tick. Prof Roy Herbst Thousands of cancer patients could be spared chemotherapy every year following significant advances in personalised medicine, experts have said. The “future of cancer treatment” is likely to […]

Read More

NHS should give all cancer patients personalised care

Life-changing personalised cancer treatments should be offered to all patients on the NHS as standard care and not be restricted to clinical trials, experts say.   Results from an international study show that genetic testing of tumours can boost survival and avoid unnecessary treatments. Despite the evidence, British scientists fear that the NHS will lag […]

Read More